Brivaracetam

Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded, along with evidence that it is around 10 times more potent for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.